{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:54:37Z","timestamp":1791863677703,"version":"4.3.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["01EW1908"],"award-info":[{"award-number":["01EW1908"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P2ZHP1\/161626"],"award-info":[{"award-number":["P2ZHP1\/161626"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heffter Young Investigator Fellowship Award","award":["HYIFA-2022-01"],"award-info":[{"award-number":["HYIFA-2022-01"]}]},{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","award":["1-190420"],"award-info":[{"award-number":["1-190420"]}],"id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss Neuromatrix Foundation","award":["2016-0111"],"award-info":[{"award-number":["2016-0111"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Research into the use of psilocybin for the treatment of psychiatric disorders is a growing field. Nevertheless, robust brain\u2013behavior relationships linking psilocybin-induced brain changes to subjective drug-induced effects have not been established. Furthermore, it is unclear if the acute neural effects are dependent on individual heterogeneity in baseline characteristics. To address this, we assessed the effects of three oral doses of psilocybin vs. placebo on cerebral blood flow (CBF) using arterial spin labeling in healthy participants (N\u2009=\u200970; n\u2009=\u200931, 0.16\u00a0mg\/kg; n\u2009=\u200910, 0.2\u00a0mg\/kg; n\u2009=\u200929, 0.215\u00a0mg\/kg). First, we quantified psilocybin-induced changes in relative and absolute CBF. Second, in an exploratory analysis, we assessed whether individual baseline characteristics and subjective psychedelic experience are associated with changes in CBF. Psychological and neurobiological baseline characteristics correlated with the psilocybin-induced reduction in relative CBF and the psilocybin-induced subjective experience. Furthermore, the psilocybin-induced subjective experience was associated with acute changes in relative and absolute CBF. The results demonstrated that inter-individual heterogeneity in the neural response to psilocybin is associated with baseline characteristics and shed light on the mechanisms underlying the psychedelic-induced altered state. Overall, these findings help guide the search for biomarkers, paving the way for a personalized medicine approach within the framework of psychedelic-assisted therapy.<\/jats:p>","DOI":"10.1038\/s41598-023-44153-z","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T16:01:43Z","timestamp":1697299303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences"],"prefix":"10.1038","volume":"13","author":[{"given":"Nathalie M.","family":"Rieser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladina P.","family":"Gubser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Moujaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Duerler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace R.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz X.","family":"Vollenweider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin H.","family":"Preller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"44153_CR1","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., B\u00e4bler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9, 3897 (1998).","journal-title":"NeuroReport"},{"key":"44153_CR2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/7854_2016_459","volume":"36","author":"KH Preller","year":"2018","unstructured":"Preller, K. H. & Vollenweider, F. X. Phenomenology, structure, and dynamic of psychedelic states. Curr. Top. Behav. Neurosci. 36, 221\u2013256 (2018).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"44153_CR3","first-page":"120","volume":"37","author":"V Beliveau","year":"2017","unstructured":"Beliveau, V. et al. A high-resolution in vivo atlas of the human brain\u2019s serotonin system. J. Neurosci. 37, 120\u2013128 (2017).","journal-title":"J. Neurosci."},{"key":"44153_CR4","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","volume":"108","author":"DE Nichols","year":"2008","unstructured":"Nichols, D. E. & Nichols, C. D. Serotonin receptors. Chem. Rev. 108, 1614\u20131641 (2008).","journal-title":"Chem. Rev."},{"key":"44153_CR5","doi-asserted-by":"publisher","unstructured":"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., ... & Malievskaia, E. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Eng. J. Med., 387(18), 1637\u20131648. https:\/\/doi.org\/10.1056\/NEJMoa2206443 (2022).","DOI":"10.1056\/NEJMoa2206443"},{"key":"44153_CR6","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402\u20131411 (2021).","journal-title":"N. Engl. J. Med."},{"key":"44153_CR7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","volume":"15","author":"AK Davis","year":"2020","unstructured":"Davis, A. K., Barrett, F. S. & Griffiths, R. R. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J. Context. Behav. Sci. 15, 39\u201345 (2020).","journal-title":"J. Context. Behav. Sci."},{"key":"44153_CR8","doi-asserted-by":"crossref","first-page":"101841","DOI":"10.1016\/j.eclinm.2023.101841","volume":"56","author":"R von Rotz","year":"2023","unstructured":"von Rotz, R. et al. Corrigendum to \u201cSingle-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial\u201d. EClinicalMedicine 56, 101841 (2023).","journal-title":"EClinicalMedicine"},{"key":"44153_CR9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"44153_CR10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J. Psychopharmacol. 30, 1165\u20131180 (2016).","journal-title":"J. Psychopharmacol."},{"key":"44153_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry 79, 953. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096 (2022).","journal-title":"JAMA Psychiatry"},{"key":"44153_CR12","doi-asserted-by":"crossref","first-page":"e35082","DOI":"10.7554\/eLife.35082","volume":"7","author":"KH Preller","year":"2018","unstructured":"Preller, K. H. et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife 7, e35082 (2018).","journal-title":"eLife"},{"key":"44153_CR13","first-page":"186","volume":"32","author":"P Duerler","year":"2021","unstructured":"Duerler, P. et al. Psilocybin induces aberrant prediction error processing of tactile mismatch responses\u2014A simultaneous EEG-FMRI study. Cereb. Cortex (New York) 32, 186\u2013196 (2021).","journal-title":"Cereb. Cortex (New York)"},{"key":"44153_CR14","doi-asserted-by":"crossref","first-page":"116980","DOI":"10.1016\/j.neuroimage.2020.116980","volume":"218","author":"FS Barrett","year":"2020","unstructured":"Barrett, F. S., Krimmel, S. R., Griffiths, R. R., Seminowicz, D. A. & Mathur, B. N. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage 218, 116980 (2020).","journal-title":"NeuroImage"},{"key":"44153_CR15","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris, R. L. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc. Natl. Acad. Sci. U.S.A. 109, 2138\u20132143 (2012).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"44153_CR16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","volume":"88","author":"KH Preller","year":"2020","unstructured":"Preller, K. H. et al. Psilocybin induces time-dependent changes in global functional connectivity: Psi-induced changes in brain connectivity. Biol. Psychiatry 88, 197\u2013207 (2020).","journal-title":"Biol. Psychiatry"},{"key":"44153_CR17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","volume":"16","author":"F Vollenweider","year":"1997","unstructured":"Vollenweider, F. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16, 357\u2013372 (1997).","journal-title":"Neuropsychopharmacology"},{"key":"44153_CR18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0893-133X(98)00089-X","volume":"20","author":"E Gouzoulis-Mayfrank","year":"1999","unstructured":"Gouzoulis-Mayfrank, E. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20, 565\u2013581 (1999).","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 2","key":"44153_CR19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-2007-979353","volume":"31","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider, F. X. Advances and pathophysiological models of hallucinogenic drug actions in humans: A preamble to schizophrenia research. Pharmacopsychiatry 31(Suppl 2), 92\u2013103 (1998).","journal-title":"Pharmacopsychiatry"},{"key":"44153_CR20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.07.020","volume":"159","author":"CR Lewis","year":"2017","unstructured":"Lewis, C. R. et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. NeuroImage 159, 70\u201378 (2017).","journal-title":"NeuroImage"},{"key":"44153_CR21","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc. Natl. Acad. Sci. U.S.A. 113, 4853\u20134858 (2016).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"44153_CR22","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.mri.2009.04.002","volume":"27","author":"M Cavu\u015fo\u011flu","year":"2009","unstructured":"Cavu\u015fo\u011flu, M., Pfeuffer, J., U\u011furbil, K. & Uluda\u011f, K. Comparison of pulsed arterial spin labeling encoding schemes and absolute perfusion quantification. Magn. Resonan. Imaging 27, 1039\u20131045 (2009).","journal-title":"Magn. Resonan. Imaging"},{"key":"44153_CR23","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1177\/0271678X19874643","volume":"40","author":"O Puig","year":"2020","unstructured":"Puig, O. et al. Comparison of simultaneous arterial spin labeling MRI and 15O\u2013H2O PET measurements of regional cerebral blood flow in rest and altered perfusion states. J. Cereb. Blood Flow Metab. 40, 1621\u20131633 (2020).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"44153_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrn.2017.48","volume":"18","author":"K Kisler","year":"2017","unstructured":"Kisler, K., Nelson, A. R., Montagne, A. & Zlokovic, B. V. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 18, 419\u2013434 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"44153_CR25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/jcbfm.2010.234","volume":"31","author":"N Khalili-Mahani","year":"2011","unstructured":"Khalili-Mahani, N. et al. Pseudocontinuous arterial spin labeling reveals dissociable effects of morphine and alcohol on regional cerebral blood flow. J. Cereb. Blood Flow Metab. 31, 1321\u20131333 (2011).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"44153_CR26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/hbm.21436","volume":"34","author":"R Handley","year":"2013","unstructured":"Handley, R. et al. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Hum. Brain Mapp. 34, 272\u2013282 (2013).","journal-title":"Hum. Brain Mapp."},{"key":"44153_CR27","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1073\/pnas.1524187113","volume":"113","author":"KH Preller","year":"2016","unstructured":"Preller, K. H. et al. Effects of serotonin 2A\/1A receptor stimulation on social exclusion processing. Proc. Natl. Acad. Sci. U.S.A. 113, 5119\u20135124 (2016).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"44153_CR28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"R Kraehenmann","year":"2015","unstructured":"Kraehenmann, R. et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol. Psychiatry 78, 572\u2013581 (2015).","journal-title":"Biol. Psychiatry"},{"issue":"Suppl 20","key":"44153_CR29","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan, D. V. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59(Suppl 20), 22\u201333 (1998).","journal-title":"J. Clin. Psychiatry"},{"key":"44153_CR30","volume-title":"Structured Clinical Interview for DSM-IV\\textregistered Axis II Personality Disorders SCID-II","author":"MB First","year":"1997","unstructured":"First, M. B., Gibbon, M., Spitzer, R. L., Williams, J. B. W. & Benjamin, L. S. Structured Clinical Interview for DSM-IV\\textregistered Axis II Personality Disorders SCID-II (American Psychiatric Pub, 1997)."},{"key":"44153_CR31","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1007\/978-0-387-79948-3_2012","volume-title":"Encyclopedia of Clinical Neuropsychology","author":"R Vaurio","year":"2011","unstructured":"Vaurio, R. In Encyclopedia of Clinical Neuropsychology (eds Kreutzer, J. S. et al.) 2447\u20132450 (Springer, 2011)."},{"key":"44153_CR32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000012333","volume":"68","author":"H Schauenburg","year":"1999","unstructured":"Schauenburg, H. & Strack, M. Measuring psychotherapeutic change with the symptom checklist SCL 90 R. Psychother. Psychosom. 68, 199\u2013206 (1999).","journal-title":"Psychother. Psychosom."},{"key":"44153_CR33","doi-asserted-by":"crossref","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus, E., Gamma, A. & Vollenweider, F. X. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE 5, e12412 (2010).","journal-title":"PLoS ONE"},{"issue":"Suppl 2","key":"44153_CR34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich, A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2), 80\u201384 (1998).","journal-title":"Pharmacopsychiatry"},{"key":"44153_CR35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.mri.2007.07.003","volume":"26","author":"Z Wang","year":"2008","unstructured":"Wang, Z. et al. Empirical optimization of ASL data analysis using an ASL data processing toolbox: ASLtbx. Magn. Resonan. Imaging 26, 261\u2013269 (2008).","journal-title":"Magn. Resonan. Imaging"},{"key":"44153_CR36","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.neuroimage.2011.10.018","volume":"59","author":"JD Power","year":"2012","unstructured":"Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L. & Petersen, S. E. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. NeuroImage 59, 2142\u20132154 (2012).","journal-title":"NeuroImage"},{"key":"44153_CR37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mri.2017.09.004","volume":"45","author":"JRC Almeida","year":"2018","unstructured":"Almeida, J. R. C. et al. Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. Magn. Resonan. Imaging 45, 26\u201333 (2018).","journal-title":"Magn. Resonan. Imaging"},{"key":"44153_CR38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/mrm.25197","volume":"73","author":"DC Alsop","year":"2015","unstructured":"Alsop, D. C. et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn. Resonan. Med. 73, 102\u2013116 (2015).","journal-title":"Magn. Resonan. Med."},{"key":"44153_CR39","first-page":"288","volume":"17","author":"Y Zan","year":"2021","unstructured":"Zan, Y., Zhang, M., Chen, K., Li, B. & Huang, Q. Differences of ASL-MRI measured cerebral blood flow among patients with AD, patients with MCI and cognitively umimpaired individuals. Alzheimer\u2019s Dementia 17, 288 (2021).","journal-title":"Alzheimer's Dementia"},{"key":"44153_CR40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eclinm.2019.04.007","volume":"10","author":"CM Cooper","year":"2019","unstructured":"Cooper, C. M. et al. Cerebral blood perfusion predicts response to sertraline versus placebo for major depressive disorder in the EMBARC trial. EClinicalMedicine 10, 32\u201341 (2019).","journal-title":"EClinicalMedicine"},{"key":"44153_CR41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","volume":"113","author":"F Holze","year":"2023","unstructured":"Holze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U. & Liechti, M. E. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clin. Pharmacol. Therap. 113, 822\u2013831 (2023).","journal-title":"Clin. Pharmacol. Therap."},{"key":"44153_CR42","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0021-9681(62)90116-9","volume":"15","author":"PD Oldham","year":"1962","unstructured":"Oldham, P. D. A note on the analysis of repeated measurements of the same subjects. J. Chronic Dis. 15, 969\u2013977 (1962).","journal-title":"J. Chronic Dis."},{"key":"44153_CR43","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/ (2018)."},{"key":"44153_CR44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser, P., Kirchner, K. & Passie, T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 29, 57\u201368 (2015).","journal-title":"J. Psychopharmacol."},{"key":"44153_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","volume":"93","author":"F Holze","year":"2022","unstructured":"Holze, F., Gasser, P., M\u00fcller, F., Dolder, P. C. & Liechti, M. E. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study. Biol. Psychiatry 93, 215. https:\/\/doi.org\/10.1016\/j.biopsych.2022.08.025 (2022).","journal-title":"Biol. Psychiatry"},{"key":"44153_CR46","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/acps.12818","volume":"136","author":"F M\u00fcller","year":"2017","unstructured":"M\u00fcller, F. et al. Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr. Scand. 136, 648\u2013657 (2017).","journal-title":"Acta Psychiatr. Scand."},{"key":"44153_CR47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.neuroimage.2013.08.048","volume":"84","author":"JD Power","year":"2014","unstructured":"Power, J. D. et al. Methods to detect, characterize, and remove motion artifact in resting state fMRI. NeuroImage 84, 320\u2013341 (2014).","journal-title":"NeuroImage"},{"key":"44153_CR48","doi-asserted-by":"crossref","first-page":"E2105","DOI":"10.1073\/pnas.1720985115","volume":"115","author":"JD Power","year":"2018","unstructured":"Power, J. D. et al. Ridding fMRI data of motion-related influences: Removal of signals with distinct spatial and physical bases in multiecho data. Proc. Natl. Acad. Sci. U.S.Am. 115, E2105\u2013E2114 (2018).","journal-title":"Proc. Natl. Acad. Sci. U.S.Am."},{"key":"44153_CR49","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.mri.2012.05.004","volume":"30","author":"Z Wang","year":"2012","unstructured":"Wang, Z. Improving cerebral blood flow quantification for arterial spin labeled perfusion MRI by removing residual motion artifacts and global signal fluctuations. Magn. Reson. Imaging 30, 1409\u20131415 (2012).","journal-title":"Magn. Reson. Imaging"},{"key":"44153_CR50","doi-asserted-by":"crossref","first-page":"116614","DOI":"10.1016\/j.neuroimage.2020.116614","volume":"212","author":"KM Aquino","year":"2020","unstructured":"Aquino, K. M., Fulcher, B. D., Parkes, L., Sabaroedin, K. & Fornito, A. Identifying and removing widespread signal deflections from fMRI data: Rethinking the global signal regression problem. NeuroImage 212, 116614 (2020).","journal-title":"NeuroImage"},{"key":"44153_CR51","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.neuroimage.2012.03.014","volume":"61","author":"R Viviani","year":"2012","unstructured":"Viviani, R., Abler, B., Seeringer, A. & Stingl, J. C. Effect of paroxetine and bupropion on human resting brain perfusion: An arterial spin labeling study. NeuroImage 61, 773\u2013779 (2012).","journal-title":"NeuroImage"},{"key":"44153_CR52","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1002\/hbm.23516","volume":"38","author":"N Khalili-Mahani","year":"2017","unstructured":"Khalili-Mahani, N. et al. Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry. Hum. Brain Mapp. 38, 2276\u20132325 (2017).","journal-title":"Hum. Brain Mapp."},{"key":"44153_CR53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1258\/ar.2012.120450","volume":"54","author":"H Kamano","year":"2013","unstructured":"Kamano, H. et al. Arterial spin labeling in patients with chronic cerebral artery steno-occlusive disease: Correlation with (15)O-PET. Acta Radiol. 54, 99\u2013106 (2013).","journal-title":"Acta Radiol."},{"key":"44153_CR54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbr.2011.06.022","volume":"225","author":"G Liakakis","year":"2011","unstructured":"Liakakis, G., Nickel, J. & Seitz, R. J. Diversity of the inferior frontal gyrus\u2014A meta-analysis of neuroimaging studies. Behav. Brain Res. 225, 341\u2013347 (2011).","journal-title":"Behav. Brain Res."},{"key":"44153_CR55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/awn279","volume":"132","author":"SG Shamay-Tsoory","year":"2009","unstructured":"Shamay-Tsoory, S. G., Aharon-Peretz, J. & Perry, D. Two systems for empathy: A double dissociation between emotional and cognitive empathy in inferior frontal gyrus versus ventromedial prefrontal lesions. Brain 132, 617\u2013627 (2009).","journal-title":"Brain"},{"key":"44153_CR56","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ijnp\/pyx047","volume":"20","author":"T Pokorny","year":"2017","unstructured":"Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I. & Vollenweider, F. X. Effect of psilocybin on empathy and moral decision-making. Int. J. Neuropsychopharmacol. 20, 747\u2013757 (2017).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"44153_CR57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/02791072.2019.1580804","volume":"51","author":"NL Mason","year":"2019","unstructured":"Mason, N. L., Mischler, E., Uthaug, M. V. & Kuypers, K. P. C. Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. J. Psychoact. Drugs 51, 123\u2013134 (2019).","journal-title":"J. Psychoact. Drugs"},{"key":"44153_CR58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0924-9338(15)30017-1","volume":"30","author":"KH Preller","year":"2015","unstructured":"Preller, K. H. et al. The effect of 5-HT2A\/1a agonist treatment on social cognition, empathy, and social decision-making. Eur. Psychiatry 30, 22 (2015).","journal-title":"Eur. Psychiatry"},{"key":"44153_CR59","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J. Psychopharmacol. (Oxford) 29, 1182\u20131190 (2015).","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"44153_CR60","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman, L., Nutt, D. J. & Carhart-Harris, R. L. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol. 8, 974 (2017).","journal-title":"Front. Pharmacol."},{"key":"44153_CR61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry 3, 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"key":"44153_CR62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz, M. P. et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J. Psychopharmacol. (Oxford) 29, 289\u2013299 (2015).","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"44153_CR63","doi-asserted-by":"crossref","first-page":"917199","DOI":"10.3389\/fpsyt.2022.917199","volume":"13","author":"K Ko","year":"2022","unstructured":"Ko, K., Knight, G., Rucker, J. J. & Cleare, A. J. Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. Front. Psychiatry 13, 917199 (2022).","journal-title":"Front. Psychiatry"},{"key":"44153_CR64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci. 21, 611\u2013624 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"44153_CR65","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/hbm.23224","volume":"37","author":"L Roseman","year":"2016","unstructured":"Roseman, L. et al. LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. Hum. Brain Mapp. 37, 3031\u20133040 (2016).","journal-title":"Hum. Brain Mapp."},{"key":"44153_CR66","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1017\/S0033291717002914","volume":"48","author":"A Schmidt","year":"2018","unstructured":"Schmidt, A. et al. Acute LSD effects on response inhibition neural networks. Psychol. Med. 48, 1464\u20131473 (2018).","journal-title":"Psychol. Med."},{"key":"44153_CR67","first-page":"461","volume":"5","author":"AK Bershad","year":"2020","unstructured":"Bershad, A. K. et al. Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 5, 461\u2013467 (2020).","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"44153_CR68","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.janxdis.2011.06.012","volume":"25","author":"N Morina","year":"2011","unstructured":"Morina, N., Deeprose, C., Pusowski, C., Schmid, M. & Holmes, E. A. Prospective mental imagery in patients with major depressive disorder or anxiety disorders. J. Anxiety Disord. 25, 1032\u20131037 (2011).","journal-title":"J. Anxiety Disord."},{"key":"44153_CR69","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10899-016-9650-6","volume":"33","author":"GI Clark","year":"2017","unstructured":"Clark, G. I., Rock, A. J., McKeith, C. F. A. & Coventry, W. L. Cue-reactive rationality, visual imagery and volitional control predict cue-reactive urge to gamble in Poker-machine gamblers. J. Gambling Stud. 33, 807\u2013823 (2017).","journal-title":"J. Gambling Stud."},{"key":"44153_CR70","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cpr.2014.03.001","volume":"34","author":"C We\u00dflau","year":"2014","unstructured":"We\u00dflau, C. & Steil, R. Visual mental imagery in psychopathology\u2014Implications for the maintenance and treatment of depression. Clin. Psychol. Rev. 34, 273\u2013281 (2014).","journal-title":"Clin. Psychol. Rev."},{"key":"44153_CR71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5127\/jep.024211","volume":"3","author":"A Arntz","year":"2012","unstructured":"Arntz, A. Imagery rescripting as a therapeutic technique: Review of clinical trials, basic studies, and research agenda. J. Exp. Psychopathol. 3, 189\u2013208 (2012).","journal-title":"J. Exp. Psychopathol."},{"key":"44153_CR72","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.brat.2008.04.009","volume":"46","author":"EA Holmes","year":"2008","unstructured":"Holmes, E. A., Lang, T. J., Moulds, M. L. & Steele, A. M. Prospective and positive mental imagery deficits in dysphoria. Behav. Res. Therapy 46, 976\u2013981 (2008).","journal-title":"Behav. Res. Therapy"},{"key":"44153_CR73","doi-asserted-by":"crossref","first-page":"102612","DOI":"10.1016\/j.nicl.2021.102612","volume":"30","author":"E Blondiaux","year":"2021","unstructured":"Blondiaux, E., Heydrich, L. & Blanke, O. Common and distinct brain networks of autoscopic phenomena. NeuroImage Clin. 30, 102612 (2021).","journal-title":"NeuroImage Clin."},{"key":"44153_CR74","doi-asserted-by":"crossref","first-page":"107666","DOI":"10.1016\/j.neuropsychologia.2020.107666","volume":"149","author":"F Garbarini","year":"2020","unstructured":"Garbarini, F., Fossataro, C., Pia, L. & Berti, A. What pathological embodiment\/disembodiment tell us about body representations. Neuropsychologia 149, 107666 (2020).","journal-title":"Neuropsychologia"},{"key":"44153_CR75","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cortex.2011.06.012","volume":"48","author":"M Gandola","year":"2012","unstructured":"Gandola, M. et al. An anatomical account of somatoparaphrenia. Cortex 48, 1165\u20131178 (2012).","journal-title":"Cortex"},{"key":"44153_CR76","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.brainres.2012.07.011","volume":"1473","author":"J Neufeld","year":"2012","unstructured":"Neufeld, J., Sinke, C., Zedler, M., Emrich, H. M. & Szycik, G. R. Reduced audio-visual integration in synaesthetes indicated by the double-flash illusion. Brain Res. 1473, 78\u201386 (2012).","journal-title":"Brain Res."},{"key":"44153_CR77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/7854_2016_461","volume":"36","author":"M Kometer","year":"2018","unstructured":"Kometer, M. & Vollenweider, F. X. Serotonergic hallucinogen-induced visual perceptual alterations. Curr. Top. Behav. Neurosci. 36, 257\u2013282 (2018).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"44153_CR78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3389\/fnhum.2013.00657","volume":"7","author":"B Brogaard","year":"2013","unstructured":"Brogaard, B. Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia. Front. Hum. Neurosci. 7, 657 (2013).","journal-title":"Front. Hum. Neurosci."},{"key":"44153_CR79","first-page":"54","volume":"6","author":"BF Gray","year":"2015","unstructured":"Gray, B. F. & Simner, J. Synesthesia and release phenomena in sensory and motor grounding. Cases of disinhibited embodiment? Front. Psychol. 6, 54 (2015).","journal-title":"Front. Psychol."},{"key":"44153_CR80","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/B978-0-12-800212-4.00083-2","volume-title":"Neuropathology of Drug Addictions and Substance Misuse","author":"B Brogaard","year":"2016","unstructured":"Brogaard, B. & Gatzia, D. E. Neuropathology of Drug Addictions and Substance Misuse 890\u2013905 (Elsevier, 2016)."},{"key":"44153_CR81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1748-6653.2011.02004.x","volume":"5","author":"L J\u00e4ncke","year":"2011","unstructured":"J\u00e4ncke, L. & Langer, N. A strong parietal hub in the small-world network of coloured-hearing synaesthetes during resting state EEG. J. Neuropsychol. 5, 178\u2013202 (2011).","journal-title":"J. Neuropsychol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44153-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44153-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44153-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:25:43Z","timestamp":1700310343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44153-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44153-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katrin H. Preller is currently an employee of Boehringer Ingelheim GmBH & CO KG. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17475"}}